SDB-006 is a drug that acts as a potent agonist for the cannabinoid receptors with an EC50 for CB1 activation of 19nM and 7x selectivity for CB1 over CB2. It was discovered during research into the related compound SDB-001 which had been sold illicitly as 2NE1.
This page contains content from the copyrighted Wikipedia article "SDB-006"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
